Valuation: Sarepta Therapeutics Inc

Market Cap 1.96B 1.75B 1.61B 1.47B 2.75B 186B 2.79B 19.45B 7.66B 97.29B 7.36B 7.2B 308B P/E 2026 *
6.24x
P/E 2027 * 81.1x
Enterprise Value 1.72B 1.53B 1.41B 1.28B 2.41B 163B 2.45B 17.02B 6.71B 85.17B 6.44B 6.3B 270B EV / Sales 2026 *
0.94x
EV / Sales 2027 * 0.97x
Free-Float
94.53%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 2026-07-27
Director of Finance/CFO 47 2025-07-15
Director of Finance/CFO 50 2020-12-13
Director TitleAgeSince
Chairman 73 2015-04-15
Director/Board Member 87 2010-05-31
Director/Board Member 67 2015-06-01
Change 5-day change 1-year change 3-year change Capi.($)
+3.19%+4.68%+61.27%+127.21% 1,133B
+4.40%+5.83%+38.93%+77.06% 621B
-0.05%+0.34%+24.35%+96.48% 503B
+0.03%+3.27%+39.79%+65.06% 379B
-1.29%+1.57%+68.33%+42.69% 370B
+1.58%+2.37%+22.91%+52.52% 292B
+2.90%+2.22%+3.51%+28.51% 262B
+2.32%+3.33%+51.53%+64.25% 237B
+2.18%-0.65%+28.72%+101.57% 190B
Average +1.63%+3.22%+37.70%+72.82% 443.11B
Weighted average by Cap. +1.96%+3.73%+43.00%+84.85%

Financials

2026 *2027 *
Net sales 1.83B 1.64B 1.51B 1.37B 2.57B 174B 2.61B 18.18B 7.16B 90.93B 6.88B 6.73B 288B 1.38B 1.23B 1.14B 1.03B 1.94B 131B 1.97B 13.7B 5.4B 68.52B 5.18B 5.07B 217B
Net income 340M 303M 280M 254M 477M 32.18B 484M 3.37B 1.33B 16.86B 1.28B 1.25B 53.41B -6.15M -5.49M -5.06M -4.6M -8.63M -582M -8.76M -60.97M -24.02M -305M -23.07M -22.58M -966M
Net Debt -244M -218M -201M -183M -343M -23.14B -348M -2.42B -955M -12.12B -917M -897M -38.41B -618M -551M -509M -462M -867M -58.5B -880M -6.13B -2.41B -30.65B -2.32B -2.27B -97.09B
Logo Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Sarepta Therapeutics Inc